top of page

Addressing the critical need for cancer-selective targets

A scarcity of novel cancer-selective targets limits effective treatment options for most patients. Current targets are generally found in small patient populations, and are also present on healthy tissue, leading to target-mediated dose limiting toxicities.

PairX unleashes the clinical impact of selective biologics

Our biology-driven, variant-specific approach reveals a new class of therapeutic targets to yield highly selective drugs that better discriminate between tumor and normal tissue for improved efficacy and best-in-class tolerability.

Novel biology-based cancer targets Paired with optimal therapeutic modalities to revolutionize cancer-selective biologics


PairX is pioneering the development of next-generation cancer-selective biologics by identifying novel, highly prevalent, tumor-selective cell surface variants. Founded on IP exclusively licensed from Duke-NUS Medical School, Singapore, we are advancing a robust pipeline of potential first- and best-in-class tumor-selective therapies targeting prevalent cancers in substantial patient populations.

Designing cancer-selective therapeutics

Novel selective targets have meaningful therapeutic windows, limit off-target effects, and often play a functional role in carcinogenesis

Targeting large proportions of patient populations

Substantial proportions of cancer patient populations harbor these variants, ensuring benefit to broader patient populations

Selecting highly actionable drug targets

Variants represent highly actionable drug targets paired with the optimal therapeutic modality

Unlocking the ability to select the most effective therapeutic modality

T-cell engagers (TCEs)

Antibody-drug conjugates (ADCs)




Variant-selective biologics offer broad treatment opportunities

Our approach offers hope to a wider range of patients living with difficult-to-treat cancers and is poised for outsized impact in areas of unmet need.


We see the opportunity for therapeutic impact in larger populations than those with specific oncogenic mutations.

And we're just getting started.


bottom of page